Skip to main content

Table 3 Frequency and incidence of events in the population with co-treatment with antiplatelets (n = 3573)

From: Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database

   Risk at 5 years    
Outcomes N (%) CI95% HR CI95% p valuea
Gastrointestinal haemorrhage
 Cilostazol 15 0.8 0.4–1.3 0.67 0.3–1.3 0.232
 Pentoxifylline 22 1.2 0.7–1.8    
Cerebral haemorrhage
 Cilostazol 14 0.8 0.4–1.2 1.23 0.6–2.7 0.604
 Pentoxifylline 13 0.7 0.3–1.1    
Other haemorrhages
 Cilostazol 55 3.1 2.3–3.9 0.65 0.5–0.9 0.014
 Pentoxifylline 85 4.8 3.8–5.8    
Any haemorrhage
 Cilostazol 69 3.8 3.0–4.7 0.72 0.5–1.0 0.040
 Pentoxifylline 98 5.5 4.5–6.6    
CAD
 Cilostazol 224 12.5 10.9–14.0 0.93 0.8–1.1 0.427
 Pentoxifylline 237 13.3 11.8–14.9    
Stroke
 Cilostazol 103 5.7 4.7–6.8 0.83 0.6–1.1 0.180
 Pentoxifylline 121 6.8 5.6–8.0    
AF
 Cilostazol 122 6.8 5.6–8.0 1.0 0.8–1.3 0.999
 Pentoxifylline 120 6.8 5.6–7.9    
Other arrhythmias
 Cilostazol 61 3.4 2.6–4.2 1.42 1.0–2.1 0.082
 Pentoxifylline 42 2.4 1.7–3.1    
  1. CI 95% Confidence Interval with 95%, HR hazard ratio, CAD coronary artery disease, AF atrial fibrillation
  2. ap-value computed using univariate Cox regression with robust standard errors by clusters (pairs)
  3. Significant p-values in boldface